BioMarin Pharmaceutical Inc. acquires Amicus Therapeutics, Inc. (2026)

Deal facts

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Announced: 27 April 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

27 Apr 2026CompletedClosed
BioMarin Pharmaceutical Inc. completes acquisition of Amicus Therapeutics, Inc.
Introductory Note As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “ SEC ”) on December 19, 2025, Amicus Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), dated December 19, 2025, with BioMarin Pharmaceutical Inc., a Delaware corporation (“ Parent
Source

OpinionExit Mode editorial

We see a definitive shift in the healthcare sector with the completed acquisition of Amicus Therapeutics by BioMarin Pharmaceutical. This transaction moves a public US life sciences company into private ownership, a structure that demands careful scrutiny from any founder considering a similar path. The deal is structured as a going-private transaction settled entirely in cash, which removes the equity risk often associated with stock-swap deals. For the SME founder reading this, the mechanics here are instructive because they prioritise certainty of value over potential future upside.

The choice of an all-cash consideration signals a clear strategic intent to consolidate rare disease portfolios without the distraction of public market volatility. In the US market, a transaction of this magnitude between two listed entities would typically trigger an immediate and rigorous review by the Federal Trade Commission under anti-trust thresholds. While the deal is now complete, the path to closure likely required navigating complex change-of-control covenants and ensuring all regulatory clearances were secured before the final transfer of ownership. This contrasts with deals that rely on earn-outs or contingent value rights, which often leave founders exposed to post-close disputes over performance metrics.

We observe that the absence of a disclosed value in the public record is unusual for a completed deal of this stature, yet the cash structure itself provides a level of transparency regarding the exit mechanism. The buyer has assumed full responsibility for the target's liabilities and future capital requirements, freeing the former shareholders from the burden of quarterly reporting. This is a significant departure from the standard public market route where founders often remain tethered to the company through lock-up periods or performance-based vesting schedules. The clean break offered by a cash buyout allows the original leadership to exit without the lingering pressure of public scrutiny.

The immediate lesson for founders preparing their own exit is to evaluate whether a cash-only structure aligns with your liquidity goals before engaging with potential buyers. You should request a term sheet that explicitly details the consideration type and confirm that the buyer has the necessary capital reserves to fund the entire transaction without relying on external financing conditions. This week, review your current cap table and identify which shareholders might prefer a guaranteed cash exit over a stock-based deal, then use that data to frame your initial discussions with prospective acquirers.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More going private deals More from BioMarin Pharmaceutical Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

16 March 2026CompletedHealthcare

REM Aggregator, LLC to acquire Quipt Home Medical Corp.

REM Aggregator, LLC and Quipt Home Medical Corp. entered the Exit Mode archive.

Buyer: REM Aggregator, LLC
Target: Quipt Home Medical Corp.
Deal value: USD 173,000,000
Deal type: going private

Read deal Healthcare deals going private deals Canada deals

Buyer history